PriceTargets.com logo

NASDAQ:HOLX - Hologic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $86.93
  • Forecasted Upside: 19.19 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$72.93 As of 10/20/2021 01:00 AM ET
▲ +2 (2.82%)

This chart shows the closing price for HOLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hologic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOLX

Analyst Price Target is $86.93
▲ +19.19% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $86.93, with a high forecast of $100.00 and a low forecast of $75.00. The average price target represents a 19.19% upside from the last price of $72.93.

This chart shows the closing price for HOLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Hologic. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021Redburn PartnersInitiated CoverageNeutralLow
8/3/2021Raymond JamesBoost Price TargetOutperform$78.00 ➝ $88.00Low
7/30/2021William BlairReiterated RatingOutperformLow
7/30/2021Morgan StanleyLower Price TargetEqual Weight$77.00 ➝ $75.00Low
7/29/2021Jefferies Financial GroupInitiated CoverageBuy$95.00Medium
7/6/2021Evercore ISIUpgradeIn-Line ➝ Outperform$78.00Low
4/30/2021Morgan StanleyLower Price TargetEqual Weight$84.00 ➝ $77.00Medium
4/29/2021CitigroupLower Price Target$90.00 ➝ $80.00Low
4/29/2021SVB LeerinkLower Price TargetOutperform$94.00 ➝ $85.00High
4/5/2021Jefferies Financial GroupBoost Price TargetBuy$106.00 ➝ $110.00Low
3/1/2021Robert W. BairdBoost Price TargetBuy$84.00 ➝ $91.00Low
2/22/2021Robert W. BairdReiterated RatingBuy$84.00 ➝ $91.00Low
2/22/2021BTIG ResearchBoost Price TargetBuy$84.00 ➝ $91.00Medium
1/28/2021Wells Fargo & CompanyBoost Price TargetOverweight$90.00 ➝ $95.00Medium
1/6/2021Raymond JamesReiterated RatingBuyN/A
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$80.00 ➝ $84.00Low
12/8/2020ArgusBoost Price Target$85.00 ➝ $100.00Low
11/20/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
11/9/2020Morgan StanleyBoost Price TargetEqual Weight$68.00 ➝ $80.00High
11/5/2020Jefferies Financial GroupBoost Price Target$80.00 ➝ $98.00Low
11/5/2020Smith Barney CitigroupBoost Price Target$90.00 ➝ $85.00Low
11/5/2020UBS GroupBoost Price TargetNeutral$77.00 ➝ $81.00Low
11/5/2020JPMorgan Chase & Co.Boost Price TargetOverweight$75.00 ➝ $85.00High
11/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$80.00 ➝ $90.00High
11/5/2020Raymond JamesBoost Price TargetOutperform$75.00 ➝ $86.00Medium
11/5/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $94.00Low
11/5/2020Needham & Company LLCBoost Price TargetBuy$78.00 ➝ $88.00Medium
8/26/2020Needham & Company LLCReiterated RatingBuy$78.00Low
7/31/2020Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $68.00Low
7/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$63.00 ➝ $80.00High
7/30/2020Raymond JamesBoost Price TargetOutperform$68.00 ➝ $78.00High
7/30/2020CitigroupBoost Price TargetPositive ➝ Buy$63.00 ➝ $85.00Low
7/30/2020SVB LeerinkBoost Price TargetOutperform$66.00 ➝ $80.00Low
7/30/2020Needham & Company LLCBoost Price TargetBuy$64.00 ➝ $78.00Low
7/29/2020BTIG ResearchReiterated RatingBuy$63.00 ➝ $84.00Low
7/27/2020William BlairReiterated RatingOutperformLow
7/23/2020Raymond JamesBoost Price TargetOutperform$62.00 ➝ $68.00Low
7/15/2020SVB LeerinkBoost Price TargetOutperform$62.00 ➝ $66.00Low
7/1/2020Needham & Company LLCInitiated CoverageBuy$60.00 ➝ $64.00High
6/30/2020CowenUpgradeMarket Perform ➝ Outperform$64.00High
6/26/2020BTIG ResearchReiterated RatingBuy$60.00Low
6/16/2020BTIG ResearchBoost Price TargetBuy$54.00 ➝ $60.00Low
6/10/2020Needham & Company LLCReiterated RatingBuyLow
6/9/2020Morgan StanleyBoost Price TargetEqual Weight$53.00 ➝ $55.00Low
6/3/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$62.00Medium
6/2/2020Needham & Company LLCInitiated CoverageBuy$60.00High
4/30/2020JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $55.00High
4/30/2020Morgan StanleyBoost Price TargetEqual Weight$40.00 ➝ $53.00High
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$48.00 ➝ $60.00High
4/30/2020BTIG ResearchBoost Price TargetBuy$46.00 ➝ $54.00High
4/30/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$41.00 ➝ $62.00High
4/30/2020Needham & Company LLCBoost Price TargetBuy$52.00 ➝ $60.00High
4/28/2020UBS GroupLower Price TargetNeutral$58.00 ➝ $52.00Low
4/19/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ OverweightMedium
4/8/2020SVB LeerinkLower Price TargetMarket Perform$57.00 ➝ $41.00High
4/8/2020Stifel NicolausLower Price TargetHold$52.00 ➝ $45.00High
4/8/2020William BlairReiterated RatingOutperformHigh
4/7/2020BTIG ResearchReiterated RatingPositive ➝ Buy$54.00 ➝ $46.00Low
4/7/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$48.00High
4/2/2020Needham & Company LLCUpgradeBuy$62.00 ➝ $52.00High
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$53.00 ➝ $40.00Low
3/26/2020BarclaysLower Price TargetEqual Weight$51.00 ➝ $43.00High
3/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$60.00 ➝ $50.00High
1/30/2020Piper SandlerBoost Price Target$58.00 ➝ $61.00Low
1/30/2020BTIG ResearchReiterated RatingBuy$54.00Medium
1/13/2020BarclaysBoost Price TargetEqual Weight$50.00 ➝ $51.00Low
1/13/2020Needham & Company LLCBoost Price TargetBuy$57.00 ➝ $62.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$57.00Low
1/6/2020CitigroupInitiated CoverageBuy$60.00Low
1/2/2020Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
12/17/2019Morgan StanleyBoost Price TargetUnderweight$45.00 ➝ $50.00Low
12/13/2019Stifel NicolausBoost Price TargetHold$48.00 ➝ $52.00Low
11/21/2019William BlairReiterated RatingBuyLow
11/20/2019SVB LeerinkReiterated RatingHold$50.00Medium
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$54.00 ➝ $59.00High
8/14/2019ArgusBoost Price TargetBuy$62.00High
8/5/2019Stifel NicolausBoost Price TargetHold$43.00 ➝ $48.00Medium
8/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$49.00 ➝ $59.00Low
8/1/2019Canaccord GenuityReiterated RatingHold$52.00Low
8/1/2019BTIG ResearchReiterated RatingBuy$52.00High
8/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $57.00High
7/10/2019Needham & Company LLCReiterated RatingBuy$52.00Low
5/2/2019BTIG ResearchReiterated RatingBuy$52.00Low
5/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $52.00Medium
4/2/2019Needham & Company LLCReiterated RatingBuy$50.00Low
1/31/2019BTIG ResearchReiterated RatingBuy$50.00High
1/31/2019Piper Jaffray CompaniesBoost Price TargetIn-Line ➝ Overweight$49.00High
1/31/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $50.00High
1/14/2019Needham & Company LLCReiterated RatingBuy$48.00Low
1/7/2019Canaccord GenuityReiterated RatingHold$41.00High
1/4/2019CowenDowngradeOutperform ➝ Market Perform$38.28Medium
1/2/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$44.00 ➝ $39.00High
11/30/2018Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $46.00Low
11/8/2018Canaccord GenuityReiterated RatingHold$43.00Low
11/8/2018Piper Jaffray CompaniesLower Price TargetOverweight$45.00N/A
10/11/2018Morgan StanleyLower Price TargetEqual Weight$47.00 ➝ $44.00Medium
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$44.00Medium
9/27/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$40.00 ➝ $41.00Low
9/27/2018Needham & Company LLCReiterated RatingBuy$48.00N/A
9/13/2018Canaccord GenuityLower Price TargetHold$41.00 ➝ $40.00Low
9/13/2018Bank of AmericaDowngradeBuy ➝ Neutral$47.00 ➝ $42.00High
9/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $43.00High
8/20/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$45.00 ➝ $43.00Low
8/14/2018Canaccord GenuityLower Price TargetHold ➝ Hold$42.00 ➝ $41.00Medium
8/13/2018Needham & Company LLCReiterated RatingBuy$48.00High
8/2/2018BTIG ResearchReiterated RatingBuy$47.00Medium
8/1/2018CowenReiterated RatingBuy$45.00Medium
8/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.00Medium
8/1/2018Jefferies Financial GroupReiterated RatingBuy$50.00Medium
8/1/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$42.00 ➝ $45.00High
8/1/2018Needham & Company LLCBoost Price TargetBuy$43.00 ➝ $48.00High
5/6/2018BTIG ResearchReiterated RatingBuy$44.00Medium
5/3/2018BarclaysLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00High
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$44.00 ➝ $42.00High
5/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$42.00 ➝ $40.00High
5/3/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$48.00 ➝ $41.00High
5/3/2018Canaccord GenuityDowngradeBuy ➝ Hold$48.00 ➝ $39.00High
5/1/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $43.00Low
4/17/2018The Goldman Sachs GroupSet Price TargetBuy$43.00Low
3/26/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$43.00Low
2/9/2018Canaccord GenuityReiterated RatingBuy$48.00Low
2/9/2018Royal Bank of CanadaReiterated RatingHold$44.00High
2/9/2018Needham & Company LLCReiterated RatingBuy$50.00High
2/9/2018Stifel NicolausDowngradeBuy ➝ Hold$45.00 ➝ $42.00High
2/1/2018Needham & Company LLCReiterated RatingBuy$50.00Low
1/19/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$49.00Medium
1/9/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $50.00Low
1/4/2018Bank of AmericaUpgradeNeutral ➝ Buy$50.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$50.00Medium
12/20/2017CowenUpgradeBuy$52.00Low
12/11/2017CowenUpgradeMarket Perform ➝ Outperform$51.00High
12/8/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$45.00 ➝ $50.00Low
12/5/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00 ➝ $48.00Low
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/A
11/3/2017Needham & Company LLCReiterated RatingBuy$50.00N/A
10/10/2017Jefferies Financial GroupReiterated RatingBuy$49.00 ➝ $44.00N/A
10/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$48.00 ➝ $45.00N/A
10/2/2017Needham & Company LLCReiterated RatingBuy$50.00Medium
9/22/2017Royal Bank of CanadaReiterated RatingHold$42.00Low
8/9/2017BarclaysReiterated RatingEqual Weight$53.00 ➝ $51.00Low
8/9/2017Royal Bank of CanadaReiterated RatingSector Perform$50.00 ➝ $45.00Low
8/3/2017BarclaysLower Price TargetOverweight$53.00 ➝ $51.00Medium
8/3/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$51.00 ➝ $49.00Medium
8/3/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$48.00 ➝ $47.00High
8/3/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$50.00 ➝ $45.00High
8/1/2017Needham & Company LLCReiterated RatingBuyMedium
7/21/2017Bank of AmericaReiterated RatingNeutral$44.00 ➝ $48.00Low
7/17/2017BarclaysReiterated RatingOverweight$50.00 ➝ $53.00Low
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$51.00Medium
7/14/2017Stifel NicolausReiterated RatingBuyMedium
6/28/2017Jefferies Financial GroupReiterated RatingBuy$49.00Low
5/28/2017Jefferies Financial GroupSet Price TargetBuy$49.00Low
5/14/2017BTIG ResearchReiterated RatingBuy$47.00Low
5/11/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$45.00 ➝ $48.00High
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00Low
4/5/2017BarclaysSet Price TargetBuy$50.00Low
4/4/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$46.00 ➝ $50.00Medium
3/30/2017SVB LeerinkReiterated RatingOutperform$52.00Low
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$51.00Low
3/13/2017Jefferies Financial GroupReiterated RatingBuy$46.00 ➝ $49.00Low
2/15/2017Needham & Company LLCUpgradeHold ➝ Buy$46.00N/A
2/15/2017Bank of AmericaDowngradeBuy ➝ NeutralN/A
2/5/2017BTIG ResearchReiterated RatingBuy$47.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$48.00N/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$48.00N/A
1/8/2017Jefferies Financial GroupReiterated RatingBuy$46.00N/A
1/4/2017Evercore ISIDowngradeBuy ➝ Hold$42.00N/A
1/4/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$44.00 ➝ $48.00N/A
12/16/2016Needham & Company LLCReiterated RatingHoldN/A
12/15/2016Canaccord GenuitySet Price TargetBuy$48.00N/A
11/19/2016BarclaysSet Price TargetBuy$45.00N/A
11/3/2016Needham & Company LLCReiterated RatingHoldN/A
11/3/2016BTIG ResearchBoost Price TargetBuy$44.00 ➝ $47.00N/A
11/3/2016BarclaysReiterated RatingBuy$45.00N/A
11/3/2016SVB LeerinkReiterated RatingTop Pick$46.00 ➝ $43.00N/A
(Data available from 10/21/2016 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2021
  • 2 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2021
  • 4 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/21/2021
  • 8 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 6 very negative mentions
Mentions as of
10/21/2021

Current Sentiment

  • 8 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 6 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Hologic logo
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment comprises products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.
Read More

Today's Range

Now: $72.93
Low: $71.26
High: $73.03

50 Day Range

MA: $75.90
Low: $69.67
High: $80.74

52 Week Range

Now: $72.93
Low: $60.10
High: $85.00

Volume

1,667,121 shs

Average Volume

2,041,031 shs

Market Capitalization

$18.49 billion

P/E Ratio

9.35

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Hologic?

The following Wall Street research analysts have issued reports on Hologic in the last year: Argus, BTIG Research, Citigroup Inc., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Redburn Partners, Robert W. Baird, Smith Barney Citigroup, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for HOLX.

What is the current price target for Hologic?

14 Wall Street analysts have set twelve-month price targets for Hologic in the last year. Their average twelve-month price target is $86.93, suggesting a possible upside of 22.6%. Argus has the highest price target set, predicting HOLX will reach $100.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $75.00 for Hologic in the next year.
View the latest price targets for HOLX.

What is the current consensus analyst rating for Hologic?

Hologic currently has 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOLX will outperform the market and that investors should add to their positions of Hologic.
View the latest ratings for HOLX.

What other companies compete with Hologic?

Other companies that are similar to Hologic include Abbott Laboratories, Medtronic, Intuitive Surgical, Stryker, Edwards Lifesciences, Becton, Dickinson and, Boston Scientific, IDEXX Laboratories, DexCom, Baxter International, ResMed, STERIS, Insulet, Teleflex and Abiomed.

How do I contact Hologic's investor relations team?

Hologic's physical mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is (508) 263-2900 and its investor relations email address is [email protected] The official website for Hologic is www.hologic.com.